Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunohistochemistry of p53 surrogates TP53 mutation as an accurate predictor for early-relapse of surgically resected stage I-III lung adenocarcinoma

15 Jun 2024

Abstract excerpt

Introduction TP53 is a strong tumor suppressor gene; its deactivation contributes to carcinogenesis and influences clinical outcomes. However, the prognostic influence of p53 deactivation on early relapse in patients with surgically resected non–small cell lung cancer remains unclear. Materials and methods A cohort of 170 patients with primary stage I through III lung adenocarcinoma (LADC) and lung squamous cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Lung Cancer Diagnosis and Treatment
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39296452
DOI: 10.1016/j.xjon.2024.06.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunohistochemistry of p53 surrogates TP53 mutation as an accurate predictor for early-relapse of surgically resected stage I-III lung adenocarcinomaPMID 39296452Read ↗

The possibility of mutations of RAS signaling genes and/or TP53 in combination as a negative prognostic impact on pathological stage I non-small cell lung cancer.Semantic proximity Read ↗

Correlation of P53 expression and TP53 mutation in stage I lung adenocarcinoma and the predictive value for postoperative recurrence within 5 yearsSemantic proximity Read ↗

A P53-Deficiency Gene Signature Predicts Recurrence Risk of Patients with Early-Stage Lung Adenocarcinoma.Semantic proximity Read ↗

Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis.Semantic proximity Read ↗

Simplified Molecular Classification of Lung Adenocarcinomas Based on <i>EGFR</i> , <i>KRAS</i> , and <i>TP53</i> MutationsSemantic proximity Read ↗

Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.Semantic proximity Read ↗

Evolutionary Action Score of TP53 Enhances the Prognostic Prediction for Stage I Lung Adenocarcinoma.Semantic proximity Read ↗

Correlative assessment of p53 immunostaining patterns and TP53 mutation status by next-generation sequencing in lung adenocarcinoma (LUAD).Semantic proximity Read ↗

EGFR Mutation Impacts Recurrence in High-Risk Early-Stage Lung Adenocarcinoma in the IASLC Grading SystemSemantic proximity Read ↗

Impact of genetic alterations on outcomes of patients with stage I nonsmall cell lung cancer: An analysis of the cancer genome atlas data.Semantic proximity Read ↗

EGFR Mutations and Recurrence Outcomes in Resected Non-Small Cell Lung Cancer: An Updated 2015-2025 Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Mutation patterns and evolutionary action score of TP53 enable identification of a patient population with poor prognosis in advanced non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.